Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bank of America Merrill Lynch Health Care

ROCKVILLE, Md.--(BUSINESS WIRE)-- Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Bank of America Merrill Lynch 2010 Health Care Conference will be webcast and may be accessed at www.hgsi.com.

A member of Human Genome Sciences’ senior management team will present a corporate overview on Tuesday, May 11, 2010, at 11:20 AM Eastern time. Investors interested in listening to the live webcast should log on before the start time in order to download any software required. The archive of the webcast will be available for several days after the live event.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company’s web site at www.hgsi.com.



CONTACT:

Human Genome Sciences, Inc.
Media:
Jerry Parrott, 301-315-2777
Vice President, Corporate Communications
or
Investors:
Peter Vozzo, 301-251-6003
Senior Director, Investor Relations

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.